Toti-N-Seq breakthrough permits common and scalable single-cell profiling

Background

The fast development of single-cell and single-nucleus RNA sequencing (sc/snRNA-seq) has opened unprecedented home windows into mobile range, but present strategies for multiplexing samples battle with scalability and accuracy. Conventional methods counting on antibodies or lipid-based barcodes typically fail to uniformly label cells throughout differing types or species, significantly in advanced medical samples. These limitations—cell-type bias, cross-contamination dangers, and lack of uncommon cell populations—hinder large-scale research and medical translation. To beat these challenges, a crew led by Professor Yiwei Li at Huazhong College of Science and Expertise (HUST) has pioneered Toti-N-Seq, a groundbreaking know-how that harnesses the common presence of N-glycans on cell and nuclear surfaces. Revealed as a canopy story in Analysis (2025, DOI: 10.34133/analysis.0678), this innovation redefines how researchers strategy high-throughput mobile profiling.

Analysis progress

On the coronary heart of Toti-N-Seq lies an engineered protein, Stv-Fg, derived from modifying the pure glycan-binding protein Fbs1. This fusion protein binds non-selectively to all N-glycan sorts, enabling common tagging of cells and nuclei. By attaching DNA barcodes to Stv-Fg, the crew achieved exact pattern multiplexing with out cell-type or species restrictions. Experimental validations underscored its robustness: stream cytometry revealed labeling efficiencies as little as 37.5 pM for cell membranes and 75.0 pM for nuclei, with cross-contamination beneath 2% even after extended pattern mixing.

In sensible functions, Toti-N-Seq demonstrated distinctive accuracy. When utilized to single-nucleus sequencing, it achieved an general classification accuracy (OCA) of 0.987, outperforming typical antibody- or lipid-based strategies. Notably, the know-how preserved uncommon cell populations, such because the 0.5% plasmacytoid dendritic cells (pDCs) in human peripheral blood samples, whereas decreasing doublet charges to 0.04% for single cells and 0.02% for nuclei. These capabilities had been additional validated in 12-plex experiments, the place pattern ratio deviations remained beneath 4%, proving its reliability for large-scale research.

Future prospects

Trying forward, the Toti-N-Seq platform is ready to remodel each primary and utilized analysis. The crew plans to develop its multiplexing capability to 24-plex or larger, facilitating formidable initiatives like cross-organ cell atlases and high-throughput drug screening. Integration with epigenetic and proteomic instruments will allow multi-dimensional single-cell analyses, shedding gentle on advanced regulatory networks.

Clinically, Toti-N-Seq’s potential to retain uncommon cell subsets positions it as a robust device for dissecting tumor microenvironments and predicting immunotherapy responses. Upcoming multi-center research will discover its diagnostic potential in most cancers affected person cohorts. Past academia, the know-how’s compatibility with platforms like MobiNova microfluidics guarantees to streamline industrial workflows, accelerating drug growth and toxicity testing by way of standardized, reproducible protocols.

Conclusion

Toti-N-Seq represents a leap ahead in single-cell genomics, addressing long-standing bottlenecks in multiplexing accuracy and scalability. By leveraging the ubiquity of N-glycans, Professor Li’s crew has created a flexible device that bridges species and cell sorts whereas preserving organic nuance. Because the know-how strikes towards medical and industrial adoption, it holds the potential to democratize high-resolution mobile profiling, empowering discoveries from developmental biology to personalised drugs.